Ascendis Pharma A/S (ASND): what the price requires

At today's price, Ascendis Pharma A/S (ASND) is priced for today's economics sustained for ~10.6 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Exported: 2026-07-20 · Source: https://boothcheck.com/report/ASND

Headline

FieldValue
TickerASND
CompanyAscendis Pharma A/S
Sector / IndustryHealthcare
Current price$261.38/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid27.4x
Steady-state operating margin assumed34.7%
Must persist for10.6y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 8.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~13.2 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.55σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings18.20x1expensive
Relative5.07x2expensive
Growth7.34x3expensive

Families that call it expensive: Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.3%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$33.687.76xyesFCF base $0.1B, growth 25% (input: historical growth), terminal g 4.0%, WACC 9.3%, 7yr projection
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$51.535.07xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$174.731.50xyesRev $0.8B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$35.597.34xyesMargin ramp: -32% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings$14.3618.20xyesFCF $58.6M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$51.535.07xyesRevenue $0.78B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$226.2m
Interest coverage-1.4x
Share count CAGR (dilution)2.7%
Burning cashno

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

The market is paying for a long ramp. At $261.38, Ascendis trades at about 27 times revenue, a price that only makes sense if you believe the business grows at its self-funding ceiling and eventually earns a high operating margin it does not yet post, and holds that combination for the better part of a decade. That is the bet. What is unusual about Ascendis is how much of it the fundamentals have already begun to validate.

Start with the revenue. First-quarter 2026 revenue reached €247 million, up from €101 million a year earlier, with YORVIPATH alone contributing €197 million and more than 1,000 new U.S. patient enrollments in the quarter. The economics that make the margin story plausible are the platform's gross margins in the high 80s, and the company reported a €25 million operating profit in the quarter, its crossover after years of losses. The cash followed the accounting: the 20-F reports free cash flow reaching "€53.9 million, representing an improvement of €360.1 million compared to last year, of which €182.0 million related to improved operating performance" [Ascendis FY2025 20-F, accession 0001193125-26-046590].

The durability rests on the platform, not a single drug. Ascendis builds every product from the same system, which it describes as "a parent drug, an inert TransCon carrier that protects it, and a TransCon linker that temporarily binds the two", releasing the parent drug slowly after injection [Ascendis FY2025 20-F, accession 0001193125-26-046590]. That is why three approvals across hypoparathyroidism, growth hormone deficiency, and now achondroplasia came from one core technology, and why the pipeline behind them shares the same engineering. For the priced-in bet to pay, the company does not need a new discovery every year. It needs the platform it already has to keep converting known biology into approved, high-margin therapies, and the February 2026 achondroplasia approval is evidence that engine still turns.

Bear Case

The capital-allocation picture sends two messages at once. In the first quarter of 2026 Ascendis spent €52 million buying back its own shares, and within a few months it was issuing stock the other direction: a June 2026 warrant-exercise window created 177,267 new shares, and the board granted a further 27,030 employee warrants struck at $213.23. Buying stock at one price while minting options at another is not by itself damning, but it sits on top of a share count that has drifted up about 2.7% a year. For a company whose entire thesis is a long, uninterrupted compounding of high-margin revenue, steady dilution is a quiet tax on every share of that future.

The headline profit flatters the operating reality. Ascendis reported a €629 million net profit for the first quarter, but €679 million of that was a one-time recognition of previously unrecognized deferred tax assets, an accounting event rather than cash from selling drugs. Underneath it, operating profit was €25 million, and the business still carries real leverage, about $226 million of net debt, with interest cover still negative on a trailing basis. A one-time $187.5 million sale of a priority review voucher padded 2026 cash, but that is a card you play once. The company's own 20-F risk factors flag continued capital needs to fund development and litigation [Ascendis FY2025 20-F, accession 0001193125-26-046590].

None of this would matter much if the runway to the priced-in bet were clear, but it is contested. Today's price requires the business to reach an operating margin near 34.7% and hold it for roughly 11 years while growing at its funding ceiling, and history is unkind to that combination: only a minority of fast growers have sustained such a pace even a decade. The competition is concrete. In achondroplasia, where Ascendis just launched, BioMarin's incumbent already holds the market, and BioMarin's own filing names Ascendis directly, noting its VOXZOGO "for the treatment of hypochondroplasia, could have competition from clinical stage products under development by Ascendis Pharma A/S" [BioMarin FY2025 10-K, accession 0001048477-26-000004]. Beyond product rivals, Ascendis concedes that "our TransCon technologies face technology-based competition as we believe other companies are developing or evaluating enhanced drug delivery and sustained release" approaches [Ascendis FY2025 20-F, accession 0001193125-26-046590]. Taking share from an established rare-disease franchise is exactly the multi-year execution the price already assumes will succeed.

Valuation

At $261.38 (July 19, 2026), Ascendis is priced against its sales rather than its profits, because the profits are only now arriving. At about 27 times revenue, the price assumes the company eventually earns an operating margin near 34.7% and grows revenue at its self-funding pace for about 11 years. The unusual feature of this bet, relative to most stocks priced this richly, is that the near-term growth rate is within what the company has recently delivered. The stretch is in how long it must persist, not how fast.

The methods disagree widely, and every one of them sits below the price. The price sits about five times peer multiples and roughly seven times the forward-growth methods as a group, and furthest of all above the earnings-power methods, unsurprising for a company whose operating profit only just crossed zero. Only one forward method, the one that carries today's revenue multiple across a decade of growth, comes anywhere near the price. The pattern is clean: this is a durability premium the static, backward-looking methods structurally cannot frame.

The balance sheet is adequate but not deep, which matters more than usual when the bet is measured in years. Cash and liquid assets stood around $702 million against gross debt near $928 million, a modest net debt position, and the share count has been rising rather than falling. The $187.5 million voucher sale and the operating-profit crossover both help, but the honest read is that the price is underwriting a decade of uninterrupted platform execution, and the balance sheet gives that decade less room for error than a stock priced this way would ideally carry.

Catalysts

The defining near-term event has already happened and now has to prove itself commercially. In February 2026 the FDA approved navepegritide as YUVIWEL for children with achondroplasia, adding a third marketed product to the platform, and the U.S. launch is underway. The two-year data from the pivotal ApproaCH trial, presented at ACMG in 2026, is the clinical backing the commercial team carries into a market where an established competitor already sells. Uptake over the next few quarters is the single most-watched line.

YORVIPATH is the current engine, and its trajectory is the other thing to watch. First-quarter U.S. enrollments topped 1,000 new patients and quarterly YORVIPATH revenue reached €197 million, so the open questions are how long the enrollment pace holds and whether pricing and persistence match the launch curve the price assumes. The next quarterly print is the readout.

On capital, the June 2026 sale of a priority review voucher for $187.5 million and the closing of a warrant-exercise window are the recent moves, both bearing on how the company funds the platform without leaning further on equity. Analyst sentiment has been constructive, with RBC Capital lifting its target to $250 on the growth outlook, a level that sits just below the current price and frames how much of the ramp the street already credits.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Ascendis FDA approval release, February 2026 · Ascendis Q1 2026 results, Form 6-K · Ascendis 6-K filings, June 2026 · Ascendis 6-K, June 2026 · Ascendis FDA approval and Q1 2026 results · Ascendis ApproaCH data release, ACMG 2026 · RBC Capital note, 2026

View the full interactive ASND report on boothcheck